Skip to main content

Advertisement

SpringerLink
Log in

Cyclooxygenase-2 Overexpression Predicts Poor Survival in Patients with High-grade Extremity Osteosarcoma: A Pilot Study

  • Original Article
  • Published:
Clinical Orthopaedics and Related Research®

Abstract

Several lines of evidence suggest cyclooxygenase-2 (COX-2) overexpression may be a causal factor for tumor growth and metastasis. However, there is no evidence COX-2 expression in a primary tumor correlates with clinical outcome of osteosarcoma. We examined expression levels of COX-2 immunohistochemically in 51 patients with extremity osteosarcoma who completed standard therapy and obtained complete initial regression of the tumor. Correlation of the positivity of staining with prognosis was analyzed. COX-2 was expressed in most of the cases. We found no correlation between COX-2 staining intensity and variables such as gender, age, anatomic site, necrosis after chemotherapy, and surgical stage. Strong COX-2 expression was associated with low metastasis-free survival. Age older than 20 years and strong COX-2 expression independently predicted increased risk of metastasis. Among seven patients with resectable lung metastasis, all three with greater COX-2 expression in the metastatic lesion than that in a primary site died of the disease. Our preliminary data suggest COX-2 overexpression in the primary tumor correlates with the occurrence of distant metastasis in patients with osteosarcoma and also may affect postmetastatic survival.

Level of Evidence: Level IV, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3A–B

Similar content being viewed by others

References

  1. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–1161.

    Article  PubMed  Google Scholar 

  2. Baldini N, Scotlandi K, Serra M, Picci P, Bacci G, Sottili S, Campanacci M. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J Orthop Res. 1999;17:629–632.

    Article  PubMed  CAS  Google Scholar 

  3. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790.

    Article  PubMed  Google Scholar 

  4. Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol. 2003;25:282–285.

    Article  PubMed  Google Scholar 

  5. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase-2 gene-expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–1188.

    PubMed  CAS  Google Scholar 

  6. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG, Taylor S. Stage-IIB osteosarcomas around the knee: a study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br. 2002;84:706–711.

    Article  PubMed  CAS  Google Scholar 

  7. Goodwin JS, Ceuppens J. Regulation of the immune-response by prostaglandins. J Clin Immunol. 1983;3:295–315.

    Article  PubMed  CAS  Google Scholar 

  8. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42:73–78.

    Article  PubMed  CAS  Google Scholar 

  9. Himelstein BP, Asada N, Carlton MR, Collins MH. Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol. 1998;31:471–474.

    Article  PubMed  CAS  Google Scholar 

  10. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90:455–460.

    Article  PubMed  CAS  Google Scholar 

  11. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6:572–577.

    PubMed  CAS  Google Scholar 

  12. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001;7:861–867.

    PubMed  CAS  Google Scholar 

  13. Lee EJ, Choi EM, Kim SR, Park JH, Kim H, Ha KS, Kim YM, Kim SS, Choe M, Kim JI, Han JA. Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. Exp Mol Med. 2007;39:469–476.

    PubMed  CAS  Google Scholar 

  14. Masi L, Recenti R, Silvestri S, Pinzani P, Pepi M, Paglierani M, Brandi ML, Franchi A. Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol. 2007;15:70–76.

    Article  PubMed  Google Scholar 

  15. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6:4064–4068.

    PubMed  CAS  Google Scholar 

  16. Naruse T, Nishida Y, Hosono K, Ishiguro N. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis. 2006;27:584–592.

    Article  PubMed  CAS  Google Scholar 

  17. Ohno R, Yoshinaga K, Fujita T, Hasegawa K, Iseki H, Tsunozaki H, Ichikawa W, Nihei Z, Sugihara K. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer. 2001;91:1876–1881.

    Article  PubMed  CAS  Google Scholar 

  18. Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY, Hawkins DS, Munsell MF, Kleinerman ES. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol. 2008;30:507–512.

    Article  PubMed  CAS  Google Scholar 

  19. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61:4375–4381.

    PubMed  CAS  Google Scholar 

  20. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol. 2006;28:33–42.

    PubMed  CAS  Google Scholar 

  21. Watkins DN, Lenzo JC, Segal A, Garlepp MJ, Thompson PJ. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J. 1999;14:412–418.

    Article  PubMed  CAS  Google Scholar 

  22. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, Shyr Y, Boothby M, Joyce S, Carbone DP, Breyer RM. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest. 2003;111:727–735.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Drs. Shigeo Nakamura and Yoshie Shimoyama for their expert opinions as pathologists. We also thank Dr. Mitsutoshi Uchibori and Eri Ishihara for help during the study.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, 466-8550, Japan

    Hiroshi Urakawa MD, Yoshihiro Nishida MD, PhD & Naoki Ishiguro MD, PhD

  2. Department of Orthopaedic Surgery, Nagoya Kyouritsu Hospital, Nagoya, Japan

    Takahiro Naruse MD, PhD

  3. Department of Orthopaedic Surgery, Aichi Cancer Center, Aichi Hospital, Aichi, Japan

    Hiroatsu Nakashima MD, PhD

Authors
  1. Hiroshi Urakawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Nishida MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahiro Naruse MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroatsu Nakashima MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoki Ishiguro MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Nishida MD, PhD.

Additional information

One or more of the authors (YN) have received funding from The Nakatomi Foundation and the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant-in-Aid 20591751 for Scientific Research [C]).

Each author certifies that his institution has approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent was obtained.

This work was performed at Nagoya University Graduate School and School of Medicine.

About this article

Cite this article

Urakawa, H., Nishida, Y., Naruse, T. et al. Cyclooxygenase-2 Overexpression Predicts Poor Survival in Patients with High-grade Extremity Osteosarcoma: A Pilot Study. Clin Orthop Relat Res 467, 2932–2938 (2009). https://doi.org/10.1007/s11999-009-0814-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11999-009-0814-x

Keywords

Search

Navigation